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Abstract
Hepatocyte growth factor (HGF) and c-met proto-oncogene product (c-Met) have varied bio-
logical functions in different tissues and have been implicated in mitogenic, motogenic and mor-
phogenic responses in both organ regeneration and carcinogenesis. Some studies have suggested
that the overexpression of c-Met and epidermal growth factor receptor (EGFR) are associated with
growth advantage, while transforming growth factor-beta receptor II (TGF beta R II) is associ-
ated with growth disadvantage of human prostatic adenocarcinoma. However, it is unclear if the
expression of c-Met correlates with the expression of EGFR and TGF beta R II, and with the pro-
liferative status of human prostatic adenocarcinoma. Using immunohistochemical staining with
anti-c-Met (C-12), anti-EGFR (NCL-EGFR) and anti-TGF beta R II (L-21) antibodies, we deter-
mined the frequency of expression of c-MET, EGFR, and TGF beta R II respectively in a series
of 134 radical prostatectomy specimens. We evaluated the relationship between the expression of
these receptors and clinicopathological characteristics. Overall, c-Met immunostaining was de-
tected in 54 of 134 (40.3%) cases, EGFR in 45 (33.6%) and TGF beta R II in 64 (48.4%). The
overexpression of c-Met was significantly more common in poorly differentiated (P< 0.0001) and
in the diffusely infiltrated specimens (P < 0.0005). In contrast, TGF beta R II was significantly
overexpressed in the well differentiated specimens (P < 0.0001) and associated negatively with
c-Met (P < 0.0001). Overall, these data suggest that c-Met/HGF receptor and TGF beta R II over-
expression may be involved in the differentiation of human prostatic adenocarcinoma, c-Met with
de-differentiation and TGF beta R II with differentiation.
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